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ABSTRACT
OBJECTIVE: The objective of this selective EBM review is to determine whether or not
“Is Tetrahydrocannabinol (THC)/Cannabidiol (CBD) oromucosal spray an effective
adjuvant therapy for Multiple Sclerosis (MS) patients who suffer from central
neuropathic pain (CNP)?”
STUDY DESIGN: Systematic review of three randomized controlled trials published
between 2005-2013, all English language.
DATA SOURCES: Three randomized controlled studies were obtained using PubMed
and MedLine.
OUTCOMES MEASURED: The outcome of each study was the subject’s incidence and
severity of central neuropathic pain compared to their baseline at the beginning of the
study. Outcomes were measured using an 11-point pain scale at various intervals. The
average scores of these participants were used to compare the control group versus the
intervention group.
RESULTS: Three randomized controlled trials and uncontrolled, extension trial were
used in this review. Langford et al demonstrated a mean difference between the
THC/CBD group and placebo-controlled group to be (odds ratio 1.31 [95% CI, 1.01-2.57
points]; P=0.046) after 10 weeks. Rog et al found that there was a statistically significant
mean reduction of pain intensity (Mean change -2.7; 95% CI: -3.4 – 2.0 (p=0.005)) in the
THC/CBD intervention group. Hoggart et al showed a significant mean reduction in pain
scores (-0.96 points; 95% CI: -1.59, -0.32, (p=0.004)) when compared to control group.
All of the results were observed in patients who were already on a stable regimen of
analgesic medications to treat neuropathic pain related to MS.
CONCLUSIONS: All three studies demonstrated statistically significant reduction in
mean central neuropathic pain with THC-CBD oromucosal spray as compared to
baseline, as well as compared to a placebo-control group. The addition of THC/CBD
oromucosal spray should be considered in MS patients who suffer from central
neuropathic pain and do not receive pain relief from standard therapy.
KEY WORDS: Multiple sclerosis (MS), Tetrahydrocannabinol (THC)/Cannabidiol
(CBD) oromucosal spray, central neuropathic pain (CNP)
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INTRODUCTION:
Treating complex medical conditions, such as Multiple Sclerosis (MS), often leads to
frustration of both the patient and the providers, because current biomedical therapies are
not adequately treating the pain. There is no known cure for MS, and with current
treatment regimens, patients are often left unable to perform normal activities of daily
living. This leads to increased dependence of others, avoidance or interference of certain
activities, increased difficulty sleeping, fatigue, depression, anxiety, increase use of
narcotics, and a higher overall perception of pain.1
MS is an immune-mediated inflammatory disorder of the central nervous system,
which leads to demyelination, glial scarring, and neuronal loss. 2 It is known to be a
widely unpredictably disease with four different progression patterns. These include
Relapsing-Remitting MS (85%), Primary-Progressive MS (10%), Secondary-Progressive
MS (85%), Progressive-Relapsing MS (5%). Among all these types of MS, central
neuropathic pain (CNP) is the most common pain syndrome. CNP is characterized by
constant, extremity pain described as “burning or stabbing,” and up to 32% rate this type
of pain as “frequent, disabling, and inadequately managed.” 3 It is estimated that
approximately 63% of all MS patients suffer from central neuropathic pain. 4
MS remains the most common cause of non-traumatic neurodisability in youth,
with the average age of onset between 20-40 years old.2 Approximately 400,000 in the
US and 2.5 million worldwide have MS. There are several risk factors for developing
MS; including genetics, female gender, Caucasian, residence further from the equator,
low vitamin D, infection, and smoking. 2 They have identified the genetic marker HLADRb1*1501 haplotype. 3
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MS ranks 2nd to CHF for the most costly chronic disease.5 When compared to
their healthy counterparts, MS patients on average are 3.5 times more likely to be
hospitalized (15.2% vs. 4.3%; p< 0.001), twice more likely to visit the ER (25.5% vs.
12.2%; p< 0.001) and 2.4 times more likely to require services from either a physical,
occupational, or speech therapist (23.7% vs. 9.9%; p < 0.001) 5. The average cost for MS
disease-modifying therapies (DMT) alone range from $8,524 - $54,244, 4 and up to an
additional $18,829 for other healthcare related costs, per year.5 These economic estimates
were derived from a systematic review of data from 1998-2008, and do not include some
of the newer, more costly MS medications.6
The current accepted treatment regimens for MS includes disease-modifying
agents such as Interferon Beta 1a and 1b (most common), Glatiramer acetate,
Mitoxantrone, Natalizumab, Fingolimod, or Teriflunomid. 8 Relapses are often treated
with high dose methylprednisone, 0.5-1g IV for 5 days. Initial treatment of CNP related
to MS should be anticonvulsants, such as carbamazepine or gabapentin. Other first line
agents include tri-cyclic antidepressants, serotonin-noepinepherine reuptake inhibitors,
and lidocaine 12 hour transdermal patches.8 When 1st line therapy fails, second line
therapies such as Lamotrigine, buproprion, citalopram, baclofen, tizanidine, and shortacting opioid therapy may be used.8 In several recent studies, THC/CBD oromucosal
spray has been shown to decrease neuropathic pain and spasticity, and has recently been
approved in Canada as an adjuvant therapy for central neuropathic pain in MS.9 This
systemic review will utilize three randomized control trials and evaluate the effectiveness
of THC/CBD oromucosal spray on MS related CNP as an adjuvant therapy for patients
who are currently optimized on other analgesic regimens without resolution of their pain.
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OBJECTIVE
The objective of this systematic review is to determine whether or not
Tetrahydrocannabinol (THC)/Cannabidiol (CBD) oromucosal spray is an effective
adjuvant therapy for Multiple Sclerosis (MS) patients who suffer from central
neuropathic pain (CNP)?
METHODS
This systematic review of three randomized control trials will investigate a patient
population greater than 18 years old, who have been previously diagnosed with Multiple
Sclerosis, and currently optimized analgesic therapy. This study will review three
THC/CBD oromucosal spray interventions from 5-14 weeks. The comparison group is
comprised of patients with MS of similar characteristics, all suffering from central
neuropathic pain, currently optimized on analgesic therapy, and utilizing a visibly
identical placebo oromucosal spray. Outcomes were measured using an 11-point
numerical pain scale. Preliminary baseline assessments were made prior to initiation of
the intervention, and reassessments took place at various intervals throughout each study.
The key words utilized in the searches were “Multiple sclerosis (MS)”,
“Tetrahydrocannabinol (THC)/Cannabidiol (CBD) oromucosal spray”, and “central
neuropathic pain (CNP).” All of the articles were researched by the author were
published in peer-reviewed journals in the English language, and were found on PubMed
and the Cochrane library. The articles were selected based off its clinical relevance to the
question posed by the author. Inclusion criteria for this systemic review included
publication date after 2005, were over 18 years old, have history of at least 6 months of
unresolved, central neuropathic pain with evidence on clinical examination, a stable pain
severity of at least 4 on the numerical pain scale, and had a stable analgesic medication
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regimen for at least two weeks prior to initiation of the study. Exclusion criteria
comprised of studies with patients who had severe non-neuropathic pain; psychiatric
conditions that may alter pain severity such as schizophrenia and psychosis; history of
substance or alcohol abuse; pregnancy or lactation; diabetes, hypertension,
cardiovascular, hepatic, renal diseases; or any cannabinoid use at least seven days prior to
the study were all excluded. The analytics used in this study were mean change from
baseline, p-values, 95% CI, and NNT.
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#Pt

Age
(yrs)

Inclusion
Criteria

Exclusion
Criteria

W/
D

Interventions

Langford1
(2013)

Double
blind
RCT

339

48.97
+
10 yrs

- CNP due to
MS x 3 months
with pain of >
24 last 6 days
- Therapies must
be stable x 2
week prior to
study

42

THC 2.7mg/CBD 2.5mg
oromucosal spray PRN.
Maximum 12 sprays per
24h.

Rog2
(2005)

Double
blind
RCT

66

48.1
+
10 yrs

-Diagnosed MS
x 6 months.
Stable central
pain x 3 months.

- Severe pain
from other
conditions
- Psychiatric
disorder, renal,
hepatic, CVD,
or convulsive
disorder
- Recent
cannabis use
- Patient’s with
chronic
visceral pain,
on TCA’s or
have psych
disorder,
Current
cannabis users,
Pregnant,
lactating, or on
levodopa.

2

THC 2.7mg/CBD 2.5mg
oromucosal spray PRN.
Self –titrated with
maximum spray 48 per
24h

Serpell3
(2011)

Double
blind
RCT

125

54.3
+
15 yrs

>18 y.o., 6
months of pain,
baseline pain
scale 4, stable
medications x 2
weeks

- Cannibis use,
Psych disorder,
nonneuropathic
pain, Diabetes,
CVD, HTN,
cancer,
terminal ill

20

THC 2.7mg/CBD 2.5mg
oromucosal spray PRN

OUTCOMES MEASURED

Self-titrated with
maximum spray 48 per
24/h
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The three randomized controlled studies’ outcomes utilized in this study was the average
perceived pain, described on an 11-point pain numerical rating scale (NRS) score. A
mean pain score for the experimental group was calculated and compared to baseline
scores at the beginning of the study. Then the mean pain scores of the experiment group
were compared to the placebo-controlled group.
RESULTS
Langford et al conducted a randomized, double blind, placebo-controlled, parallel-group
study, which comprised of 339 patients with MS, and were randomized into an
interventional group (n= 167) and a placebo-controlled group (n=172).10 Each participant
was instructed on proper medication delivery during a 1-week baseline period, followed
by a 14 week treatment phase, where they self-titrated to a maximum of 12 sprays per 24
hours.10 Participants were required to do daily self-reporting of their CNP using an 11point numerical rating pain scale (NPS). At the end of the 14-week treatment phase, all
participants were invited to begin a open treatment phase (n=58), which consisted of a 2week re-titration and 12-week stable dose phase with THC/CBD spray.10 At the end of
the open trial, participants were entered in a double-blind, randomized withdrawal trial to
determine the long term efficacy of THC/CBD, and the presence and severity of any side
effects. 10
Results of the study determined that there was no significant difference between
the placebo-controlled and intervention group at baseline. 10 After 10 weeks of treatment,
there was a statistically significant difference between the intervention and control
group’s in favor of the THC.CBD spray (odds ratio 1.61 [95% CI: 1.01-2.57]: p= 0.046).
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At the end of the 14-week treatment phase, there was not a statistically significant

difference between interventional and placebo-controlled group, with a difference of 0.17 points in favor of THC/CBD spray (odds ratio 1.31 [95% CI: 0.84 – 2.04]: p=
0.234).10 At the end of the open-trial phase, there was a statistically significant change in
mean pain scare, with a difference of -0.79 points in favor of THC/CBD spray (90% CI: 1.37 to – 0.21 points; p=0.028). 10. Statistically significant data was considered in pvalues less than 0.05. 3% of the THC:CBD, and 1% of the placebo groups developed
sever adverse events (AE) that led to cessation of the treatment, but did not reach a
statistically significant difference (p = 0.69).10 The most common reported AE was GI
discomfort. Data was provided by Langford et al, and NNT and NNH (tables 4 and 5)
were calculated by the author.
Table 2: Comparison of Control vs. THC/CBD Intervention after 10 and 14 weeks 10
10 weeks

14 weeks

Number of Responders with at
the 30% improvement level in
mean CNP NPS

THC ~ 50%

THC- 50%

Placebo ~ 40%

Placebo- 45%

p-value; 95% CI

P = 0.046

P = 0.234

Table 3: Comparison of Primary and Secondary Endpoints 10

Control
THC/CBD
Intervention
p- value
Mean Change
in NPS

Baseline CNP
NPS
6.61 (+/- 1.29)

14 week CNP NPS from
baseline
-1.76 (6.61 + 1.29-4.73 + 2.26)

Randomized- Withdrawal CNP
NPS from baseline
-0.03 (6.21 + 1.37)

6.55 (+/- 1.35)

-1.93 (6.55 +1.35-4.54 + 2.24)

+0.76 (6.49 + 1.31)

N/A
+0.06

P = 0.47
-0.17

P= 0.028*
-0.79

Table 4: Numbers needed to treat 10
Relative risk
reduction (RRR)

Absolute risk
reduction

Number needed to
treat (NNT)
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(ARR)
EER – CER
CER
0.11

EER - CER
0.05

1/ARR
20

Table 5: Numbers needed to harm (rate of adverse events) 10
Relative risk
increase (RRI)
EER- CER
CER
0.29

Absolute risk
increase (ARI)
EER - CER
0.02

Number needed to
harm (NNH)
1/ARI
50

Rog et al., conducted a study evaluating 66 patients with MS CNP and their
response to THC:CBD oromucosal spray as an adjuvant therapy. In this 5-week,
randomized, double blind, placebo-controlled, parallel-group study, 64 patients were
randomized into an interventional group (n=34) and a visually identical placebo group
(n=32). 11 Each participant underwent a toxicity screening, using up to 4 sprays over 2
hours. Patients who passed the intoxication screening were entered in a 1-week dosing
optimization period, where they titrated up to a maximum of 48 sprays in a 24-hour
period.11 The baseline mean pain score was recorded in the 7 days prior to the
intoxication screening, using an 11-point pain NRS score.11 During weekly telephone
follow-ups, patient’s reported pain severity was averaged, then compared to the average
pain recorded the last week of treatment.
Results of the study determined that there was no significant difference between
the placebo-controlled and intervention group at baseline. 11 After the 5 week, the study
demonstrated a statistically significant difference between the placebo-controlled and the
interventional group, in favor of the THC:CBD oromucosal spray (-1.25 [95% CI: -2.11
to -0.39]; p=0.005).11 The study also collected data to determine their numbers needed to
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treat and numbers needed to harm (tables 7 and 8). During the study 88.2% of CBD:THC
vs 68.8% of placebo groups developed AE’s. The most common AE’s were dizziness and
confusion, which did not reach a statistically significant difference (0.19; 95% CI: 0.000.39; p=0.053).11 Statistically significant data was considered in p-values less than 0.05.
The data in tables 6-8 were provided by Rog et al. 11
Table 6: Comparison of Control vs. THC:CBD intervention after 5 weeks 11
Baseline (95% CI)

Primary Endpoint (95% CI)

Placebo-Controlled

6.37 (5.77- 6.97)

4.96 (4.19 – 5.72)

THC:CBD Intervention

6.58 (6.00 -7.15)

3.85 (3.13 –4.58)

p-value

p = 0.005

Table 7: Numbers needed to treat (NNT)11
Odd’s Ratio: 3 (95% CI: 2.2 to 13)

Table 8: Numbers needed to harm (NNH)11
At least 1 Adverse Event

1/ Risk Difference; Odds Ratio; CI; p-value
1/0.19 = 5 (0.19; CI: 0.00-0.39; p = 0.53)

Serpell et al., conducted a 5 week randomized, double-blind, placebo-controlled
parallel-group study which evaluated 125 patients with MS CNP, and their response to
THC:CBD oromucosal spray as an adjuvant therapy. Patients were randomized into the
THC:CBD intervention group (n=63) and visibly identical placebo-controlled group
(n=62). 12 Patients entered in a one-week dose optimization period, where they titrated up
to a maximum of 48 sprays in 24 hours. An average baseline pain NRS score was
collected in the 7 days prior to the first dosing and was compared to the mean pain score
of each week, or 3 days prior to withdrawal. 12
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Results of the study determined that there was no significant difference between
the placebo-controlled group and the intervention group at baseline. 12 After the 5 week
intervention, the study demonstrated a statistically significant difference between the
placebo-controlled and the intervention group, in favor of the THC:CBD oromucosal
spray (-0.96 [95% CI: -1.59 to -0.32] p= 0.004). 12 AE’s reported reached a statistical
significance difference between the two groups was reported for nausea (THC/CBD 49%
vs placebo 32%; p= 0.003). The study also collected data to determine the numbers
needed to treat at 30% and 50%, as well as the numbers needed to harm (tables 10 and
11). Statistically significant data was considered in p-values less than 0.05. The data in
tables 9-11 were provided by Serpell et al. 12
Table 9: Comparison of Control vs. THC:CBD intervention after 5 weeks 12
Baseline (95% CI)
Placebo-Controlled

7.2 (1.5)

Estimated Mean Difference
(95% CI)
- 0.52 (-1.59 to -0.32)

THC:CBD Intervention

7.3 (1.4)

-1.48 (-1.59 to -0.32)

p-value

p = 0.004

Table 10: Numbers needed to treat (NNT) 12
NNT (30% pain reduction)
NNT (50% pain reduction)

8 patients
8 patients

Table 11: Numbers needed to harm (NNH) 12
Relative risk
Absolute risk
Number needed to
increase (RRI)
increase (ARI)
harm (NNH)
EER- CER
EER - CER
1/ARI
CER
0.90

.10

10

DISCUSSION
In this three-study review was able to show that THC:CBD oromucosal spray is an
effective adjunctive therapy for MS related CNP. The Langford, 2013 study failed to
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meet a statistically significant difference at their primary endpoint, however an
intermediate endpoint, which more closely represented studys conducted by Rog et al.
and Serpell et al, (10 weeks vs. 5 weeks), were able demonstrate a statistically significant
difference in the THC:CBD oromucosal spray, suggesting a stronger placebo response
after 10 weeks. 10
These studies also indicated that THC:CBD oromucosal spray is a safe drug to
use for adjuvant therapy in this population of MS patients with CNP.11 Of those who
suffered from AE’s, most were considered mild to moderate, and at the completion of the
study, the majority of AE’s were no longer present. In the Langford 2013 study, a 14
week open-trial treatment using THC:CBD oromucosal spray, as well as a double blind,
placebo-controlled 4 week withdrawal trial, was conducted to determine long-term
efficacy of the spray, and identify any withdrawal symptoms that may present. They
concluded that THC:CBD oromucosal spray had a statistically significant mean reduction
in pain and time to treatment failure10
A limiting factor identified in these studies is a small sample size that was taken
in the studies (339, 64, 125) 10,11,12 and the results may not accurately reflect the
population’s response to THC:CBD oromucosal spray therapy. Studies also indicate a
strong placebo effect that may have taken place. This may be contributed to the unlimited
daily dosing for the placebo controlled group in all the studies, versus a maximum daily
dosage for the THC:CBD oromucosal spray groups.10. Statistical analysis may have also
been affected by the maximum permitted daily dosage for the THC:CBD oromucosal
spray which differed between the studies, (24 vs. 48 sprays), and may have altered the
participant’s perceived analgesic effect.
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Another limiting factor to consider is the multiple etiologies of “neuropathic pain,” and
no accepted diagnostic criteria, or bed-side exams that exists to determine if the patient’s
pain is neuropathic in nature. 13 Some studies accept spasm-related MS pain as
neuropathic while others do not. 13 Therefore, you could hypothesize that all etiologies of
MS-related pain could benefit from THC:CBD oromucosal spray. To enhance
homogeneity of future study subjects, a standardized, diagnostic criterion should be to
determined to identify neuropathic pain from other pain etiologies.
Finally, it is important to note that THC:CBD oromucosal spray is currently in phase III
clinical trials and is not currently available for purchase in the United States, and thus not
covered by any US healthcare insurer. 8 Current Federal government regulations make
marijuana use illegal in all 50 states, however state governments have approved
medicinal marijuana in 24 states. 8
CONCLUSION
This small systematic review was able to determine that the use of THC:CBD
oromucosal in MS related pain, is an effective adjuvant therapy in patients who are
currently optimized on pain medication. 10, 11, 12 Future studies should attempt to identify
diagnostic criteria for neuropathic pain, provide a maximum daily dosage for both the
THC:CBD oromucosal spray and placebo, and continue to investigate the safety and
effectiveness of THC:CBD oromucosal spray in MS related pain. Currently there are no
clinical trials using THC:CBD oromucosal spray on MS related CNP.
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